BCR

About

Location: 22q11.23

Mappings

HGNC: HGNC:1014

Ensembl: ENSG00000186716

NCBI: 613

Refseq: NM_004327.4

View API

Biomarkers

BCR is involved in the following curated biomarkers.

Name Biomarker type Propositions Statements
BCR::ABL1 Gene fusion 17 50

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
EMA (1) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
EMA (1) FDA (2) ABL1 p.T315I, BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Asciminib
EMA (5) FDA (2) CD19 +, not BCR::ABL1 Acute Lymphoblastic Leukemia Blinatumomab
EMA (3) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Bosutinib
EMA (3) FDA (6) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Dasatinib
FDA (4) BCR::ABL1 Acute Lymphoblastic Leukemia Dasatinib
EMA (2) FDA (4) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Imatinib
FDA (4) BCR::ABL1 Acute Lymphoblastic Leukemia Imatinib
EMA (3) FDA (6) BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Nilotinib
EMA (1) FDA (2) BCR::ABL1 Acute Lymphoblastic Leukemia Cytarabine, Dexamethasone, Methotrexate, Ponatinib, Prednisone, Vincristine
FDA (2) ABL1 p.T315I, BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (2) FDA (2) ABL1 p.T315I, BCR::ABL1 Chronic Myeloid Leukemia, BCR-ABL1+ Ponatinib
EMA (2) CD22 +, not BCR::ABL1 Acute Lymphoblastic Leukemia Inotuzumab ozogamicin
EMA (2) not BCR::ABL1 Acute Lymphoblastic Leukemia Imatinib
EMA (1) not BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (1) ABL1 p.T315I, not BCR::ABL1 Acute Lymphoblastic Leukemia Ponatinib
EMA (2) not BCR::ABL1 Acute Lymphoblastic Leukemia Dasatinib